Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas

Human Pathology

Volumn 43, Issue 8, 2012, Pages 1206-1212

  Fassan, Matteo ^a   Ludwig, Kathrin ^a   Pizzi, Marco ^a   Castoro, Carlo ^a   Guzzardo, Vincenza ^a   Balistreri, Mariangela ^a   Zaninotto, Giovanni ^a   Ruol, Alberto ^a   Giacomelli, Luciano ^a   Ancona, Ermanno ^a   Rugge, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adenocarcinoma; HER2; Immunohistochemistry; ISH

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; DISEASE ASSOCIATION; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; ESOPHAGUS CANCER; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MALE; PHENOTYPE; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84863985197     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.09.004     Document Type: Article

References (24)

1. T.G. Paulson, and B.J. Reid Focus on Barrett's esophagus and esophageal adenocarcinoma Cancer Cell 6 2004 11 16 (Pubitemid 38903158)
2. G. Zaninotto, F. Minnei, and E. Guirroli The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results Dig Liver Dis 39 2007 18 25 (Pubitemid 46024553)
3. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
4. F. Fiorica, D. Di Bona, and F. Schepis Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis Gut 53 2004 925 930 (Pubitemid 38824146)
5. D. Cunningham, W.H. Allum, and S.P. Stenning Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
6. S.R. DeMeester Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment Ann Surg Oncol 13 2006 12 30
7. V. Gebski, B. Burmeister, and B.M. Smithers Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis Lancet Oncol 8 2007 226 234 (Pubitemid 46291702)
8. A. Ruol, C. Castoro, and G. Portale Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution Arch Surg 144 2009 247 254
9. H.K. Koeppen, B.D. Wright, and A.D. Burt Overexpression of HER2/neu in solid tumours: an immunohistochemical survey Histopathology 38 2001 96 104 (Pubitemid 32194449)
10. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
11. L. Albarello, L. Pecciarini, and C. Doglioni HER2 testing in gastric cancer Adv Anat Pathol 18 2011 53 59
12. T. Takehana, K. Kunitomo, and K. Kono Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay Int J Cancer 98 2002 833 837 (Pubitemid 34286677)
13. M. Tanner, M. Hollmén, and T.T. Junttila Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 2005 273 278 (Pubitemid 40309309)
14. D.I. Park, J.W. Yun, and J.H. Park HER-2/neu amplification is an independent prognostic factor in gastric cancer Dig Dis Sci 51 2006 1371 1379 (Pubitemid 44315804)
15. C. Gravalos, and A. Jimeno HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 2008 1523 1529
16. M. Hofmann, O. Stoss, and D. Shi Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805 (Pubitemid 351724903)
17. J.D. Barros-Silva, D. Leitão, and L. Afonso Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients Br J Cancer 100 2009 487 493
18. A.H. Marx, L. Tharun, and J. Muth HER-2 amplification is highly homogenous in gastric cancer Hum Pathol 40 2009 769 777
19. J.E. Boers, H. Meeuwissen, and N. Methorst HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) Histopathology 58 2011 383 394
20. Y. Hu, S. Bandla, and T.E. Godfrey HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma Mod Pathol 24 2011 899 907
21. C. Bozzetti, F.V. Negri, and C.A. Lagrasta Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma Br J Cancer 104 2011 1372 1376
22. U. Reichelt, P. Duesedau, and M.C.h. Tsourlakis Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus Mod Pathol 20 2007 120 129 (Pubitemid 44967957)
23. F. Bosman, F. Carneiro, R. Hruban, and N. Theise WHO classification of tumours of the digestive system 2010 IARC Press Lyon, France
24. M. Fassan, F. Rea, M. Pizzi, and M. Rugge HER-2/neu expression is consistent in primary and metastatic lung adenocarcinoma Lung Cancer 71 2011 371 372